Eef Schimmelpennink, Lenz Therapeutics CEO

Lenz Ther­a­peu­tics eyes bet­ter vi­sion than Ab­b­Vie, Ora­sis with $80M+ for three PhI­II tri­als

Lenz Ther­a­peu­tics thinks it can de­liv­er a bet­ter eye drop than Ab­b­Vie’s Vuity and Ora­sis Phar­ma­ceu­ti­cals’ CSF-1, un­der FDA re­view. And the San Diego biotech has $83.5 mil­lion to test those am­bi­tions in three Phase III tri­als.

The late-stage stud­ies are un­der­way and will read out da­ta on about 800 pa­tients to­ward the end of this year and ear­ly 2024, pres­i­dent and CEO Eef Schim­melpen­nink told End­points News on Tues­day morn­ing. The fi­nanc­ing will bankroll the com­pa­ny for at least two and a half years, he added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.